Repare Therapeutics shares rise 32.12% intraday after XenoTherapeutics agrees to $1.82/share acquisition with contingent value rights.

Repare Therapeutics Inc. surged 32.12% intraday following the announcement of its acquisition by XenoTherapeutics for $1.82 per share, including contingent value rights (CVRs), and a transition to private ownership. The deal, set to close in Q1 2026, offers shareholders immediate cash and future value from existing partnerships, while Repare’s Q3 earnings turned positive (8c EPS) and revenue rose to $11.6M, signaling financial improvement. The stock’s sharp intraday rally reflects investor optimism over the premium acquisition price ($1.82 vs. $1.65 trading price) and potential upside from CVRs tied to licensing milestones. Despite a TD Cowen downgrade to Hold, the acquisition’s structural certainty and earnings turnaround drove the intraday buying frenzy, as traders capitalized on the arbitrage opportunity and anticipated delisting-related volatility.